Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings

2018 ◽  
Vol 56 (09) ◽  
pp. 411-416
Author(s):  
Karel Kostev ◽  
Emile Schokker ◽  
Louis Jacob
Sign in / Sign up

Export Citation Format

Share Document